Week of August 24, 2026 · 10 stocks
AI's plumbing runs the table while silver rips past $70
The week belonged to the picks-and-shovels of the AI build-out — edge networks, synthetic DNA, datacenter hosts — while a silver breakout and a roaring crypto bid dragged everything risk-on along with them.
Roughly a million mentions moved across the ~1,900 names we track this week, and the conversation ran on two engines. The first was AI infrastructure: Cloudflare reporting that AI agents now generate more than half its network traffic, Twist Bioscience getting anointed by Anthropic, Bitdeer finally putting a dollar figure on its datacenter pivot. The second was a broad risk-on rip — Bitcoin near $77k made Robinhood the single loudest name on the board, silver's charge to $70 lit up the miners, and the crypto bid got loud enough to hijack a fistful of equity tickers (VeChain posing as $VET, a Base memecoin as $KAI — we cut those). Here are the ten genuine names the crowd couldn't stop talking about.
Cloudflare printed the kind of quarter that rewrites a thesis. The August 18 report showed revenue up 36% to $696M, a raised full-year guide near $2.87B, and one genuinely startling line: non-human AI-agent traffic crossed 50% of everything moving across its network for the first time. The stock popped 16%.
Here's the wrinkle. A large slice of the $NET feed this week wasn't about the edge-network business at all, but a Robinhood-chain token trading under the same symbol, with callers touting a 5x and 'hockey stick' runs toward $500-800. Strip the token noise and the actual equity debate is quieter — a Palantir-style argument over paying ~40x sales for 30% growth.
The data backs the picks-and-shovels story: 73% gross margins, agentic AI turning Cloudflare from useful into load-bearing. It also backs the skeptics — at 38-43x sales, perfection is priced. The October 29 print is the referee.
No name was louder — 429,000 posts, the single biggest volume on the board — and the fuel was obvious: Bitcoin ripping toward $77,000 dragged Robinhood up double digits inside 48 hours. CEO Vlad Tenev added an accelerant with an August 18 op-ed pressing US regulators to legalize tokenized equities, noting overseas tokenized-stock volume is up more than 800% this year.
The tape is loudly, almost giddily bullish — a tokenization 'supercycle,' Robinhood Chain past $1B in TVL, some 400,000 net-new funded customers in June. The lone bear was a misreported Tom Lee 'avoid HOOD' note that Fundstrat's own strategist walked back within the day.
Underneath the story sits a real business now: revenue up 15% to $1.07B at a 46% operating margin and $1.2B of free cash flow. But at a 39x multiple and a beta north of two, this trades as a leveraged bet on crypto staying in trend — and co-founder Baiju Bhatt has quietly sold about $9.5M into the move. November 4 tells the next chapter.
Silver went nearly vertical — spot punched through $70 an ounce on August 21, up from about $57 at July's end — and Hecla, the largest US silver producer, did what high-torque miners do in the fat part of a cycle. It led the group up 47% on the month, roughly double the metal itself.
The crowd sees a clean theme and says so without hedging: a 'crystal-clear' setup, a Wolfe Wave pointed at $25, and no visible bear willing to stand in front of it.
The fundamentals mostly cooperate — Q1 revenue up 57% to $411M, 62% gross margins, a debt-free balance sheet and record free cash flow, up 169% over twelve months. The asterisk is a slightly light Q2 EPS, and the deeper truth that this is a spot-price trade, not a compounder: the run needs silver to hold above $65. November 4 is the check.
Cypherpunk Technologies did something no company had: it stood up the world's largest Zcash mining fleet at 4.2 Gsol/s, making itself simultaneously the biggest ZEC treasury and the biggest ZEC miner. Cantor Fitzgerald nearly doubled its target to $1.60, and the stock ran from $0.68 to $1.07.
The mood is pure small-cap euphoria — traders openly floating $10, the Winklevoss backing waved around as validation, and not a bear in sight.
The fine print matters as much as the chart here: this is a zero-revenue treasury proxy, up 416% on the year, that moves violently on Zcash's price and little else. Grayscale-ETF chatter hints at a 200,000-ZEC contribution from DCG, which is the real institutional anchor — and the flip side of that leverage is genuine tail risk. The November 11 print has to show the mining ramp is on schedule.
BioNTech's move was borrowed, not earned. When Merck and Moderna posted a Phase 3 cancer-vaccine win, the German mRNA pioneer caught the sympathy wave — a 22% single-day jump and $BNTX 120-strike calls printing 240%.
The bulls frame it as one of only two true end-to-end mRNA platforms, alongside Moderna. The skeptics circulate a LEERINK note arguing BNTX should fade precisely because it isn't in the specific Merck-Moderna readout, and they point at BioNTech's own history of neoantigen-vaccine misses.
The financials read 'company in transition': Q1 revenue down 34% to $120M as COVID demand evaporates, and a FY26 loss estimate near -$4.49 while the pipeline gets rebuilt on old vaccine cash. The event that actually matters is BioNTech's late-stage lung-cancer readout at WCLC — sympathy trades tend to unwind fast when the primary catalyst leaves them out. November 3.
Antero Resources is coiling on a story the market keeps under-pricing: Appalachian natural gas heading into winter with the AI-power-and-LNG demand narrative tightening the balance behind it. The chart chatter is technical — a monthly tweezer bottom at support, a consolidating gas group.
The equity read leans bullish, though $AR is another symbol catching crypto crossfire this week; you have to filter the Arweave posts out of the stream to hear the gas thesis at all. On the name itself, no real bear voice.
The numbers are why the coil is interesting: Q1 revenue up 34% to $1.86B, 40% gross margins, $830M of free cash flow and a 16% FCF yield against a single-digit forward multiple. That is a cash machine getting almost no credit for the demand setup. The October 28 print, straight into winter, is the catalyst.
DoorDash spent two years quietly turning a food-delivery app into a general retail marketplace, and this week the market started paying for it. Gap, Barnes & Noble, Carter's and Kohl's all landed on the platform, stacking high-frequency non-food orders onto the core.
Traders are reading the chart as a coiled spring — an inside-bar close pressed against $222.5 trendline resistance, riding a price-target upgrade and a beat setup. (As with a few names this week, you sift the Dash-coin posts out of the $DASH tape first.)
The fundamentals justify the optimism: Q1 revenue up 33% to $4.04B at 51% gross margins, a marketplace still outgrowing its own category. A confirmed break above $225 opens the recent $240+ highs; the November print and any color on vertical take-rates decide whether the extension holds. A couple of founder J-Other filings sit in the background, typically trust transfers rather than open-market sales.
Twist Bioscience makes synthetic DNA, and on August 18 it became the house that grades the machines' work: Anthropic tapped it as independent evaluator for AI-designed proteins, whose designs hit their targets 40% of the time versus 3.7% for human experts. Shares jumped roughly 20% on the news and are up more than 340% since the deep-dive.
The feed is jubilant — talk of five- and six-baggers, biotech shorts getting torched. The honest counter comes from Scorpion Capital, which argues Twist is a commodity contract lab 'hired to manufacture,' not a strategic AI partner.
Growth is real — revenue up 19% to $111M at 52% gross margins — but the stock sits at 100% of its 52-week range while insiders monetize hard: officer Patrick Finn sold $9.2M and CEO Emily Leproust another $2.5M into the highs, better than $12M of fresh supply. The November 13 print lands with the name at all-time highs and that selling still on the tape.
FutureFuel is a recovery story with receipts. A May fire knocked its biofuel plant offline; Q2 showed the comeback — 8.4 million gallons produced versus 2.0 million in Q1 despite a three-week outage, roughly 75% utilization, and a swing back to a $0.25 profit that made it the NYSE's top percentage gainer on the day.
Bulls like the trajectory: RINs pricing runs higher in Q3 than Q2, utilization is pointed toward 85%, and while one early caller booked about 42% and walked, others are staying for a chemicals-segment reversion.
The catch is coverage — there's essentially no sell-side here, so the small-cap trades on primary disclosure rather than consensus, up roughly 50% over the year with a debt-free balance sheet and a token dividend. The November print, and whether utilization holds above 85%, is the whole ballgame.
Bitdeer handed the Bitcoin-miner-to-AI-host pivot the one thing it lacked — a number. A five-year, roughly $400M AI-datacenter offtake covering about half its Malaysia A102 facility turns 'miner with a slide deck' into 'AI-cloud host with a book of business,' and the sell-side noticed: Barclays opened at Overweight with a $15 target, Needham sits at $20.
The crowd is firmly in, framing BTDR as the standout against CLSK and MARA, with unusual flow running through the October $12 calls.
The financials still wear the transition: Q1 revenue up 169% to $189M, but a -20% gross margin and -$440M of quarterly free cash flow — profitability is a 2027-2028 event. Two officers bought stock on the open market in August, and Tether anchors 19.7% of the equity. The November 9 print, and the A102 timeline holding, is the proof point that separates it from a generic miner.
Attention is a leading indicator, not a crystal ball — see who's talking, and what the data says back, live on TickerTalks.
Want this live, not weekly?
See what's trending right now →TickerTalks is a research tool, not financial advice. This recap describes what accounts on X are discussing — it is not a recommendation to buy or sell any security. Social attention is not predictive of future price moves; investing involves risk of loss.
